IL305125A - Multi-substituent psilocybin derivatives and methods of using - Google Patents
Multi-substituent psilocybin derivatives and methods of usingInfo
- Publication number
- IL305125A IL305125A IL305125A IL30512523A IL305125A IL 305125 A IL305125 A IL 305125A IL 305125 A IL305125 A IL 305125A IL 30512523 A IL30512523 A IL 30512523A IL 305125 A IL305125 A IL 305125A
- Authority
- IL
- Israel
- Prior art keywords
- group
- nucleic acid
- acid sequence
- seq
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/0102—Diaminopimelate decarboxylase (4.1.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/0102—Tryptophan synthase (4.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149001P | 2021-02-12 | 2021-02-12 | |
| US202163247881P | 2021-09-24 | 2021-09-24 | |
| PCT/CA2022/050206 WO2022170438A1 (en) | 2021-02-12 | 2022-02-11 | Multi-substituent psilocybin derivatives and methods of using |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL305125A true IL305125A (en) | 2023-10-01 |
Family
ID=82838865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305125A IL305125A (en) | 2021-02-12 | 2022-02-11 | Multi-substituent psilocybin derivatives and methods of using |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11918594B2 (enExample) |
| EP (1) | EP4291549A4 (enExample) |
| JP (1) | JP2024506667A (enExample) |
| KR (1) | KR20230157342A (enExample) |
| AU (1) | AU2022218921A1 (enExample) |
| CA (1) | CA3208152A1 (enExample) |
| IL (1) | IL305125A (enExample) |
| MX (1) | MX2023009491A (enExample) |
| WO (1) | WO2022170438A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| CA3219577A1 (en) * | 2021-05-27 | 2022-12-01 | Nicholas Stuart William MILNE | Methods for producing tryptamine derivatives. |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| GB202315025D0 (en) * | 2023-09-29 | 2023-11-15 | Psylink Uab | Production and medical use of psilocybin and related compounds |
| WO2025099444A1 (en) * | 2023-11-09 | 2025-05-15 | Beckley Psytech Limited | N-Acetylserotonin (NAS) Analogues |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3182071A (en) * | 1961-06-27 | 1965-05-04 | Warner Lambert Pharmaceutical | Acylated indole derivatives |
| US4803218A (en) * | 1982-09-29 | 1989-02-07 | Mcneilab, Inc. | 3-aminoalkyl-1H-indole-5-urea and amide derivatives |
| DK1859798T3 (en) * | 2001-03-29 | 2016-03-21 | Lilly Co Eli | N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor |
| ATE553190T1 (de) * | 2006-02-22 | 2012-04-15 | Brain Biotechnology Res & Information Network Ag | Neue halogenase |
| US10138205B2 (en) * | 2015-02-19 | 2018-11-27 | University Of Florida Research Foundation, Incorporated | Artificial self-sufficient cytochrome P450s |
| KR101934048B1 (ko) * | 2017-03-09 | 2019-03-26 | 고려대학교 산학협력단 | 플라빈-의존형 할로게나아제 및 이를 이용한 할로겐화 인돌 화합물의 제조방법 |
| US11591627B2 (en) * | 2018-03-21 | 2023-02-28 | University Of Florida Research Foundation, Incorporated | Modified bacteria for production of nitroaromatics |
| CA3132731A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| WO2021226416A1 (en) * | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| WO2022047583A1 (en) * | 2020-09-02 | 2022-03-10 | Magicmed Industries Inc. | Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder |
| WO2022115944A1 (en) * | 2020-12-01 | 2022-06-09 | Magicmed Industries Inc. | Carboxylated psilocybin derivatives and methods of using |
-
2022
- 2022-02-11 KR KR1020237031136A patent/KR20230157342A/ko active Pending
- 2022-02-11 EP EP22752044.2A patent/EP4291549A4/en active Pending
- 2022-02-11 WO PCT/CA2022/050206 patent/WO2022170438A1/en not_active Ceased
- 2022-02-11 AU AU2022218921A patent/AU2022218921A1/en active Pending
- 2022-02-11 MX MX2023009491A patent/MX2023009491A/es unknown
- 2022-02-11 JP JP2023548816A patent/JP2024506667A/ja active Pending
- 2022-02-11 IL IL305125A patent/IL305125A/en unknown
- 2022-02-11 CA CA3208152A patent/CA3208152A1/en active Pending
- 2022-09-29 US US17/956,139 patent/US11918594B2/en active Active
-
2023
- 2023-12-20 US US18/390,228 patent/US12133856B2/en active Active
- 2023-12-20 US US18/390,195 patent/US12128058B2/en active Active
-
2024
- 2024-09-19 US US18/890,082 patent/US20250025483A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024506667A (ja) | 2024-02-14 |
| KR20230157342A (ko) | 2023-11-16 |
| AU2022218921A9 (en) | 2024-01-11 |
| WO2022170438A1 (en) | 2022-08-18 |
| US12133856B2 (en) | 2024-11-05 |
| US20250025483A1 (en) | 2025-01-23 |
| MX2023009491A (es) | 2023-10-13 |
| CA3208152A1 (en) | 2022-08-18 |
| US11918594B2 (en) | 2024-03-05 |
| US20230270768A1 (en) | 2023-08-31 |
| US20240122950A1 (en) | 2024-04-18 |
| US20240173340A1 (en) | 2024-05-30 |
| EP4291549A1 (en) | 2023-12-20 |
| US12128058B2 (en) | 2024-10-29 |
| AU2022218921A1 (en) | 2023-09-21 |
| EP4291549A4 (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11918594B2 (en) | Multi-substituent psilocybin derivatives and methods of using | |
| US11998557B2 (en) | Halogenated psilocybin derivatives and methods of using | |
| US11931338B2 (en) | Nitrilated psilocybin derivatives and methods of using | |
| US12187679B2 (en) | Hydroxylated psilocybin derivatives and methods of using | |
| US11891359B2 (en) | Prenylated psilocybin derivatives and methods of using | |
| CA3191095A1 (en) | Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder | |
| US12605361B2 (en) | Carboxylated psilocybin derivatives and methods of using | |
| US20260103442A1 (en) | Aminated psilocybin derivatives and methods of using | |
| WO2024178504A1 (en) | Tri-halo-alkoxy-substituted tryptamine derivatives and methods of using | |
| WO2023102659A1 (en) | Glycosylated isopropylamine mescaline derivatives and methods of using | |
| Zeringo | Biochemical and structural studies of the circadian enzymes CLOCK and casein kinase 1, and indolotryptoline biosynthetic enzymes |